Trial Profile
A Randomized Phase II, Open-Label Multicenter Trial of Panobinostat Monotherapy in Women With HER2 Positive Locally Recurrent or Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Panobinostat (Primary)
- Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 01 Apr 2022 This trial has been completed in France (End Date: 22 March 2010) according to European Clinical Trials Database record.
- 04 Jul 2012 Planned number of patients changed from 132 to 140 and additional trial locations (France, United Kingdom) added as reported by European Clinical Trials Database.
- 21 May 2010 Actual patient number (4) added as reported by ClinicalTrials.gov.